The study revealed a lower risk of nephrolithiasis with SGLT2 inhibitors than DPP4 inhibitors in both stone never-formers and ...

Solute carrier kidney transporter (SLC ... compounds can be inhibited in a dose-dependent manner by well-known SLC inhibitors, indicating that the overexpressed kidney transporters are functioning ...

SGLT2 inhibitors are a new family of ... to over 50% of total endogenous glucose release. Renal glucose reabsorption involves two transporter families: the SGLTs secondary active Na + /D-glucose ...

Administering transporter inhibitors like cimetidine and pyrimethamine can block the excretion of creatinine. In vivo, these inhibitors also reduce the renal clearance of metformin by blocking OCT ...

Starting SGLT2 inhibitors led to a lower risk of eGFR decline or incident kidney failure. SGLT2 inhibitors were also linked to reduced amputation and AKI risks. Use of SGLT2 inhibitors was ...

Use of proton pump inhibitors appears to increase the risk for kidney failure among patients with CKD. Use of proton pump inhibitors (PPIs) may spur progression to kidney failure in patients with ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

The prevalence of diabetes and chronic kidney disease was 99.3% and 57.3%, respectively. Compared with DPP-4 inhibitor use, SGLT2 inhibitor use was associated with a significantly lower risk for ...

Adding probenecid, an OAT1 inhibitor, reduces PAH clearance due to drug-drug interactions at the transporter level. As part of a collaborative project, Newcells has examined renal toxicology after ...

Objective: To determine the cost–effectiveness of ACE inhibitor therapy in nondiabetic proteinuric patients with advanced renal disease in Germany. Methods: Two strategies were compared ...